Loading...
Searching Database & Compiling the results...
This process involves analyzing complex genetic data and may take a moment.
PDX model details
| PDX ID | 395M |
|---|---|
| Host Strain(and Source) | NSG Source: Monash University |
| Host Strain Immune system Humanized | NO |
| Host Type | Testosterone supplemented |
| Graft Site | Subcutaneous |
| Current Generation (* indicates number of generations grown in Castrate host) |
8 |
| Average PDX Generation Time (days +/- SEM) | 158 ± 14 |
| Tumour preparation | Tumor solid |
| Tumour Characterization Technology | Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin | Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed | Routine QA every 2-3 passages |
| Associated meta data | |
| PDX model availability | Yes (fixed, frozen) |
| Governance restriction for distribution | Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID | 34413304 |
| Markers | 395M |
|---|---|
| AR | Y |
| PSA | Y |
| PSMA | Y |
| NE | N |
| ERG | N |
This table displays curated CNVs
| PDX ID | Gene Symbol | CNV Log2 | CNV Copy | CNV Call | Experiments name | Platform | Reference genome |
|---|---|---|---|---|---|---|---|
| 395M | XPO1 | -1.124 | 0.917 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 395M | RB1 | -1.149 | 0.902 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 395M | ZFHX3 | -0.952 | 1.034 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 395M | CDK12 | -1.221 | 0.858 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 395M | KEAP1 | -1.233 | 0.851 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 395M | PIK3CB | 0.526 | 2.880 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 395M | PIK3CA | 0.526 | 2.880 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 395M | MET | 0.573 | 2.975 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 395M | BRAF | 0.573 | 2.975 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 395M | EZH2 | 0.573 | 2.975 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 395M | KMT2C | 0.573 | 2.975 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
Clinical Information
| Sample Number | 395M |
|---|---|
| Sample Site | Suprapubic mass |
| Sample source | Surgery |
| Pathology Tumour Diagnosis | None |
| Gleason Score | None |
| Primary Gleason Score | None |
| Secondary Gleason Score | None |
| Tertiary Gleason Score | None |
| ISUP Grade Group | |
| Tumour Grade | |
| D'Amico Risk Classification | |
| Tumour Volume (in cc) | 0.0 |
| Treatment Prior to Specimen Collection | None |
Patient Information
| Patient Number | 395 |
|---|---|
| Sex | Male |
| Diagnosis | Prostate Cancer |
| PSA at diagnosis (ng/mL) | NA |
| Consent to share data | Yes, subject to ethical review |
| Patient Tumour Collection (Current Model) | |
|---|---|
| Tumour sample ID | 395M |
| Patient Age (binned in 5 year age groups) | 65-69 |
This table displays curated sequence variants
| PDX ID | Gene Symbol | Total Read Depth | Alternate Frequency | Consequence | Exon | GnomAD AF | CADD PHRED score | ClinVar significance | Platform | Experiments Name | Reference | Library Type | Instrument Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 395M | NOTCH1 | 554 | 0.5 | Missense variant | '34/34 | 2.91E-05 | 27.3 | Uncertain significance | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 395M | POMC | 495 | 0.49 | Missense variant | '3/3 | 4.07E-06 | 24.1 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 395M | JPH2 | 546 | 0.49 | Missense variant | '1/6 | . | 31 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 395M | ZFHX3 | 105 | 0.47 | Inframe insertion | '10/10 | . | . | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 395M | CSMD1 | 534 | 0.47 | Missense variant | '14/70 | . | 27.2 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 395M | KMT2D | 460 | 0.46 | Stop gained | '9/54 | . | 35 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 395M | MSH6 | 365 | 0.43 | Missense variant | '4/10 | 8.57E-05 | 25.7 | Conflicting interpretations of pathogenicity | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 395M | MSH6 | 370 | 0.43 | Missense variant | '4/10 | 0.0003834 | 25.5 | Uncertain significance | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 395M | TNXB | 303 | 0.35 | Missense variant | '10/13 | . | 32 | Uncertain significance | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 395M | TNXB | 303 | 0.35 | Missense variant | '10/13 | . | 32 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 395M | FOXA1 | 416 | 0.29 | Inframe deletion | '2/2 | . | . | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
No information in Drug dosing Table